Pantarhei Oncology BV (PRO) is a limited liability company (‘Besloten Vennootschap’) located in the Netherlands with an innovative approach towards drug development in cancers sensitive for endocrine treatment or immunotherapy.
PRO is a subsidiary company of Pantarhei Bioscience BV.
The company has developed a sustainable product pipeline based on its ability to identify novel medical uses of existing molecules, drugs, hormones, biologicals or combinations thereof in these areas of medicine. The main areas of expertise of PRO are breast cancer, prostate cancer and ovarian cancer.
The business model of PRO is based on creating intellectual property (IP) of new treatment concepts and providing in-house project management. All research and development activities are outsourced. PRO develops patent protected treatments up to proven efficacy and safety (proof-of-concept) in the human (phase II). Using existing molecules often provides first evidence of safety. After successful proof-of-concept, data and IP are licensed-out to a licensee or (pharmaceutical) partner for final development (phase III), regulatory approval and commercialisation.